Clinical study
Clinical validation of DDS
Scientific expertise
Regulatory expertise
specific CDNF
neurosurgical expertise
concept of CDNF protein therapy
patented European innovation CDNF
PD
intracerebral drug delivery
disease modification
existing clinical experience
unmet clinical needs
Clinical trial applications
Proof
efficacy study of intracerebrally administered CDNF protein therapy
patented European innovation DDS
strong interdisciplinary expertise
PET imaging expertise specific
Parkinsonâ€™s disease
Parkinson's disease
GMP manufacturing expertise of novel biological drug compounds
significant potential
tested device
targeted intracerebral infusions
related data
novel means
related neurosurgery
neurosurgically implanted Drug Delivery System
ER stress related indications
novel neurotrophic factors
innovative European technologies
chronic diseases
scientific advice
significant impact
tested approach
regulatory authorities
TreatER project
unique goals
independent goals
medical device development
non-human primates
chronic toxicology studies
main focus of TreatER
excellent safety profile
patients
extensive preclinical research
knowledge available
consortium
MHRA
accordance
countries
Finland
UK
EMA's ITF
Sweden
placebo
treatment